Can-Fite Biopharma Ltd (NASDAQ:CANF) Expected to Announce Earnings of -$0.80 Per Share

Share on StockTwits

Equities analysts expect Can-Fite Biopharma Ltd (NASDAQ:CANF) to post ($0.80) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma reported earnings of ($0.90) per share during the same quarter last year, which suggests a positive year over year growth rate of 11.1%. The business is expected to report its next quarterly earnings report on Friday, August 30th.

On average, analysts expect that Can-Fite Biopharma will report full-year earnings of ($1.49) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.32) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Can-Fite Biopharma.

Can-Fite Biopharma (NASDAQ:CANF) last announced its quarterly earnings results on Wednesday, May 29th. The company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.94) by $0.74. The business had revenue of $0.30 million for the quarter.

Separately, HC Wainwright reissued a “buy” rating on shares of Can-Fite Biopharma in a report on Tuesday, March 26th.

Shares of CANF traded up $0.06 during midday trading on Thursday, reaching $3.10. 204,751 shares of the stock were exchanged, compared to its average volume of 126,536. Can-Fite Biopharma has a twelve month low of $2.66 and a twelve month high of $25.95. The firm has a 50 day moving average of $2.95.

About Can-Fite Biopharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Read More: How to start trading in the forex market?

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

First Trust SMID Cap Rising Dividend Archievers ETF   Shares Down 0.6%
First Trust SMID Cap Rising Dividend Archievers ETF Shares Down 0.6%
Emerald Health Therapeutics   Shares Down 5.3%
Emerald Health Therapeutics Shares Down 5.3%
Biotricity  Stock Price Up 1.7%
Biotricity Stock Price Up 1.7%
Choiceone Financial Services  Shares Up 1%
Choiceone Financial Services Shares Up 1%
Aencoin  Tops 24-Hour Volume of $64,693.00
Aencoin Tops 24-Hour Volume of $64,693.00
RealTract Price Hits $0.0018 on Exchanges
RealTract Price Hits $0.0018 on Exchanges


 
© 2006-2019 Zolmax.